Biotech M&A – 2024 Deals

Biotech M&A – 2024 Deals

Biotech M&A With a Quick Start in 2024!

Is There Any Chance to Beat 2023 Numbers ?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/08/2024MerckMRKHarpoon TherapeuticsHARP$680M$23.00 delta-like ligand 3 (DLL3) targeting T-cell
01/08/2024Johnson & JohnsonJNJAmbrx BiopharmaAMAM$2B$28.00PSMA-Targeting Antibody Drug Conjugate (ADC)
01/08/2024Boston ScientificBSXAxonicsAXNX$3.7B$71.00 urology- to treat urinary and bowel dysfunction
01/08/2024NovartisNVSCalypso Biotech BVPrivate$250M-anti-IL-15 monoclonal antibody, ermatology, gastro-intestinal
01/09/2024GSKGSKAiolos BioPrivate$1B-$400M milestone
respiratory pipeline
01/23/2024SanofiSNYInhibrx, Inc.INBX$1.7B$30+$5 CVR+ 1/4sharesRare disease asset for Alpha-1 Antitrypsin Deficiency-AATD
2/12/2024Gilead GLD CymaBay Therapeutics CBAY$4.3B$32.50PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC)
02/16/2024XOMA CorporationXOMAKinnate BiopharmaKNTE$2.3352 + $0.2527 CVR
03/14/2024AstraZenecaAZNAmolyt PharmaPrivate$1.05B-Ph3 chronic hypoparathyroidism
03/19/2024AstraZenecaAZNFusion PharmaceuticalsFUSN$2.4B$21 + $3 CVRradioconjugate targeting PSMA for prostate cancer
03/25/2024Novo NordiskNVOCardior PharmaceuticalsPrivateup to 1.025B Euros-CDR132L in Ph2 for the treatment of heart failure
03/25/2024AbbVie ABBVLandos BiopharmaLABP$137.5M + ~$75M CVR$20.42 + $11.14 CVRNX-13, oral NLRX1 agonist in Ph2 for the treatment of ulcerative colitis (UC)
04/03/2024GenmabGMABProfoundBio, Inc.Private$1.8BNext-generation ADCs in FRα-expressing solid tumors
04/10/2024VertexVRTXAlpine Immune SciencesALPN$4.9B$65Povetacicept for IgA Nephropathy Treatment
04/23/2024IncyteINCYEscient PharmaceuticalsPrivate$750M -oral MRGPRX4 antagonist
04/29/2024ONO Pharmaceutical-JapanOPHLYDeciphera PharmaceuticalsDCPH$2.4B $25.60switch-control inhibitor for the treatment of 4L GIST tumor
05/16/2024Johnson & JohnsonJNJProteologix, Inc.Private$850M- atopic dermatitis (AD)
05/29/2024MerckMRKEyeBioPrivate$1.3Bup to $1.7 billion in future milestoneLate-phase candidate for diabetic macular edema

For M&A 2023 full table click here

Recent Press


Log In

JoinLost Password?